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Abstract
Subretinal delivery of polyethylene glycol-substituted lysine peptide (CK30PEG)-compacted DNA nanoparticles results in
efficient gene expression in retinal cells. This work evaluates the ocular safety of compacted DNA nanoparticles. CK30PEG-
compacted nanoparticles containing an EGFP expression plasmid were subretinally injected in adult mice (1 ml at 0.3, 1.0
and 3.0 mg/ml). Retinas were examined for signs of inflammation at 1, 2, 4 and 7 days post-injection. Neither infiltration of
polymorphonuclear neutrophils or lymphocytes was detected in retinas. In addition, elevation of macrophage marker F4/80
or myeloid marker myeloperoxidase was not detected in the injected eyes. The chemokine KC mRNA increased 3–4 fold in
eyes injected with either nanoparticles or saline at 1 day post-injection, but returned to control levels at 2 days post-
injection. No elevation of KC protein was observed in these mice. The monocyte chemotactic protein-1, increased 3–4 fold
at 1 day post-injection for both nanoparticle and saline injected eyes, but also returned to control levels at 2 days. No
elevations of tumor necrosis factor alpha mRNA or protein were detected. These investigations show no signs of local
inflammatory responses associated with subretinal injection of compacted DNA nanoparticles, indicating that the retina
may be a suitable target for clinical nanoparticle-based interventions.
Citation: Ding X-Q, Quiambao AB, Fitzgerald JB, Cooper MJ, Conley SM, et al. (2009) Ocular Delivery of Compacted DNA-Nanoparticles Does Not Elicit Toxicity in
the Mouse Retina. PLoS ONE 4(10): e7410. doi:10.1371/journal.pone.0007410
Editor: Alfred Lewin, University of Florida, United States of America
Received May 18, 2009; Accepted September 10, 2009; Published October 12, 2009
Copyright:  2009 Ding et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by funding from NEI (EY-017031: XQD and EY018656: MIN), FFB, Inc. (MIN), Ocst(MIN), and the state of Ohio Biomedical
Research and Commercialization Program (MJC). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: xi-qin-ding@ouhsc.edu
¤a Current address: Charlesson, LLC, Oklahoma City, Oklahoma, United States of America
¤b Current address: The University of Kansas Medical Center, Kansas City, Kansas, United States of America
Introduction
Inherited retinal degenerative diseases are a major cause of
blindness worldwide. Defects in a large number of genes can cause
retinal degenerative disorders (http://www.sph.uth.tmc.edu/
RetNet/disease.htm), butthere arecurrently no effective treatments
for the diseases. Due to the monogenic nature of many inherited
retinal diseases, gene replacement/correction therapy is one of the
most promising treatment options. Viral-meditated gene delivery
and therapy has been successful in various animal models and it is
currently generating promising results in clinic trials [1,2]. For
example, restoration of retinal function by viral-mediated gene
delivery was documented in canine (RPE65
2/2 dog) [3,4] and
mouse models of Leber Congenital Amaurosis, in mouse models of
retinitis pigmentosa (rd mice) [5], and in mouse models of complete
achromatopsia (Gnat2
2/2 mice) [6]. Human patients have shown
improvement after delivery of ciliary neurotrophic factor by
intraocular implant [7] and after viral delivery of RPE65 [1,2,8].
Inspiteofthesesuccesses,safetyconcernshave increasinglysurfaced
for viral vector-mediated gene transfer, and some trials have
resulted in oncogenesis or even mortality [9,10] (albeit non-ocular
trials). Additionally, broad application of traditional viral gene
delivery can be hindered by limitations in the size of the expression
cassette to be transferred, host immunity to repeat infections, and
the possibility of insertional mutagenesis [10,11]. A recent report
showing that retinal delivery of the viral vectors has resulted in viral
vectorDNAinthe brain[12] wouldraisea concern regardinguseof
viralvectorsintheeye.Thewidespreaddevelopmentofviralvectors
forclinicaluse alsofacespracticalandeconomicalchallenges.There
are more than 140 genes that cause retinal degenerative disorders,
many of which contain multiple single disease causing mutations.
For gene replacement therapy, each additional gene requires the
development of a new vector (viral or non-viral). Given the time and
expense involved in generating and testing viruses, the development
of a less expensive alternative such as nanoparticles is beneficial.
Recently a variety of non-viral gene delivery systems have been
developed to supplement the available viral treatment options.
One such approach is the use of DNA condensed with
polycationic polymers. Compacted DNA nanoparticles with
different formulations have been shown to be efficient in gene
transfer to a number of tissues [13,14,15]. One particularly
successful formulation consists of a single molecule of plasmid
DNA compacted with polyethylene glycol (PEG)-substituted
polylysine (CK30PEG) [16]. These nanoparticles are effective in
delivering genes to dividing and post-mitotic cells and have a
plasmid capacity of at least 20 kbp [16,17]. They efficiently deliver
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repeatedly dosed without decrement in biologic activity [15,18].
These nanoparticles have been used in a phase I/II clinical trials
to deliver the cystic fibrosis transmembrane regulator (CFTR)
gene to cystic fibrosis (CF) patients [19] and are also being
developed for treatment of genetic brain diseases [20]. Recently,
we have demonstrated successful ocular delivery of these
CK30PEG nanoparticles (containing a CMV-EGFP vector,
pZEOGFP5.1) [14]. The nanoparticles were targeted to different
tissues within the eye by varying the site of injection; almost all cell
types of the eye were capable of being transfected. Of particular
interest for the treatment of inherited retinal degenerations,
subretinal delivery of these nanoparticles transfected nearly all of
the photoreceptor population and did not cause irreversible defects
in retinal function (as measured by electroretinogram (ERG)) [14].
Our most recent studies have demonstrated that these nanopar-
ticles can be used to provide partial structural and functional
rescue of a retinitis pigmentosa disease phenotype after subretinal
delivery to the diseased mouse eye [21].
These encouraging results make further analysis of the safety and
toxicity of these nanoparticles critical. This step has not been
undertaken and is necessary for the progress of this technology and
the development of novel nanoparticle based treatments. While the eye
has traditionally been considered an immune privileged tissue, it does
exhibit immune reactivity under certain stresses and is prone to
environmentally-induced alterations. Although we have previously
shown that retinal function (ERG recordings) was not affected by
delivery of the nanoparticles [14], no effort has been made to learn how
the local tissues respond to the nanoparticles and whether there is a
local toxic or inflammatory response. To that end, the purpose of this
work was to evaluate any retinal inflammatory or cellular toxic
responses to nanoparticle administration. Here we report that
subretinal delivery of DNA nanoparticles does not induce inflamma-
tory infiltrates or significant levels of cytokines. These findings suggest
that ocular delivery of DNA nanoparticles is a safe approach for future
clinical testing for the treatment of inherited retinal degeneration.
Results
Expression of Transgene
Retinal expression of EGFP following subretinal delivery of
CMV-EGFP (CK30PEG pZEOGFP5.1) nanoparticles was exam-
ined by immunofluorescence labeling using anti-GFP antibody.
Figure 1 shows representative images of EGFP expression in the
retinal sections at 2 days post-injection (PI-2). EGFP immunore-
activity was detected in inner segments (IS) and in the outer
nuclear layer (ONL). No immunoreactivity was detected in saline-
injected eyes or in retinal sections that had been incubated with
normal IgG (Figure 1). Consistent with previous experiments using
this vector [14], transgene expression was not detected at PI-4 or
PI-7. The short duration of transgene expression is likely related to
the rapid silencing of the CMV promoter. We have observed
much longer duration of transgene expression after a single
delivery of these nanoparticles (up to one year) when other
promoters such as the interphotoreceptor retinoid binding protein
promoter or the chicken beta-actin promoter are used.
Infiltration and Activation of Inflammatory Cells
To determine whether there was a local inflammatory response
to the nanoparticles we examined infiltration and activation of
inflammatory cells following subretinal injection. Infiltration of
inflammatory cells such as polymorphonuclear leukocytes (PMN)
is an early and acute response to toxic stimuli in the eye [22,23]. It
is likely that if there was a local inflammatory response to the
nanoparticles, it would be most pronounced near the injection site.
Indeed identifying the precise injection site is quite difficult. The
standard transvitreal subretinal injection procedure will create a
localized detached region near the injection site in the central-
temporal region for the right eye and the central-nasal region for
the left eye. However, because detachment can also be caused by
histological processing, the detached region cannot be definitively
marked as the injection site. In our analysis we evaluated sections
taken throughout the entire eye and examined areas both near and
far from the injection site.
We examined the cross-sections of eyes that had been injected
with nanoparticles or saline and performed hematoxylin and eosin
(H&E) staining. From these evaluations we did not find clear
infiltration of PMN or other inflammatory cells in the injected
eyes. Figure 2A are representative images of H&E stained retinal
sections showing areas near the injection site. Lower magnification
images of the same areas are shown in Figure S1. In these assays,
murine eyes with experimentally induced Bacillus cereus endoph-
thalmitis [24,25] and murine eyes with experimentally induced
corneal keratitis (by adenovirus type 37, Ad-37) [26] were included
as positive controls for infiltration of PMN. As shown in Figure 2B,
Figure 1. Immunofluorescence detection of EGFP expression in mouse retinas following subretinal delivery of compacted DNA
nanoparticles or saline. Immunofluorescence labeling using anti-GFP was performed on paraffin-embedded sections. Shown are representative
images of EGFP immunolabeling on the retinal sections of eyes that had been injected with 1.0 mg nanoparticles or with saline at PI-2.
Immunoreactivity was detected in the IS, ONL, and OPL layers. Retinal sections were also incubated with normal IgG as negative control. RPE, retinal
pigment epithelium; OS, outer segment; ONL, outer nuclear layer; OPL, outer plexiform layer; INL, inner nuclear layer; GCL, ganglion cell layer. Scale
bar, 50 mm.
doi:10.1371/journal.pone.0007410.g001
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endophthalmitis eyes (middle panel) and in corneal section of
Ad37-infected eyes (right panel). No infiltration was detected on
retinal sections (left panel) of untreated eyes.
Subsequently, we examined levels of the myeloid marker
myeloperoxidase (MPO) in the retinas of injected eyes. MPO is
the most abundant component of azurophilic granules in
neutrophils [27] and is also found in the lysosomes of monocytes,
PMN leukocytes, and macrophages [28]. During stimulation,
MPO is secreted by these cells and activates cellular inflammatory
signaling cascades [29]. If there is a local inflammatory response
and PMN infiltration following subretinal delivery of nanoparti-
cles, MPO will be activated and released. Thus we examined
MPO distribution in the retina by immunohistochemistry
following nanoparticle treatment and we found no MPO
immunoreactivity in the nanoparticle injected retinal sections.
Figure 3A are representative images of the immunohistochemical
labeling showing areas near the injection site. Lower magnification
images of the same areas are shown in Figure S2. MPO
immunoreactivity was markedly elevated in the positive controls
(Figure 3B), but there was no detectable MPO signal in either
saline or nanoparticle dosed retinas.
Figure 2. Histological examination of inflammatory cell infiltration in mouse retinas following subretinal delivery of compacted
DNA nanoparticles or saline. A. Shown are representative images of H&E stained retinal sections of eyes injected with nanoparticles (1.0 and
3.0 mg) or saline at 1, 2, 4 and 7 days PI. No infiltration of inflammatory cells was detected in the injected retinas. B. Shown are representative images
of control assays. Infiltrating cells were detected in retinal sections of Bacillus cereus endophthalmitis eyes (middle panel, shown by arrows) and in
corneal sections of Ad37-infected eyes (right panel, shown by arrows). No infiltration was detected on retinal section of untreated eyes (left panel).
OS, outer segment; ONL, outer nuclear layer; INL, inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer; CE, corneal epithelium; CS,
corneal stroma; EN, corneal endothelium. Scale bar, 50 mm.
doi:10.1371/journal.pone.0007410.g002
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F4/80 [30,31] in retinas that had been injected with nanoparticles.
Induction of F4/80 in response to ischemia-induced retinopathy has
been described in mouse retina [32]. F4/80 has also been implicated
in experimental choroidal neovascularization [33]. Immunofluores-
cence labeling was performed to determine F4/80 distribution in the
retina. As shown in Figure 4A–B, no F4/80 immunoreactivity was
detected in nanoparticle or saline injected retinas at any time point or
dose. Lower magnification images of the same areas are shown in
Figure S3. In contrast, a robust expression of F4/80 was detected in
the positive controls (Figure 4C). The absence of microglia/
macrophage activation (Figure 4) combined with the observed lack
of PMN infiltration (Figure 2) and MPO activation (Figure 3) suggests
that there is no local inflammatory response to the nanoparticles.
Expression of Inflammatory Chemokines
The eye is immune-active and prone to environmental alterations
including infection [26], oxygen-induced retinopathy [34], ischemic
injury [35] and neovascularization [36]. Interleukin-8 (IL-8/KC),
monocyte chemotactic protein-1 (MCP-1) and tumor necrosis factor
alpha (TNF-a) are the pro-inflammatory chemokines known to be
involved in the ocular inflammatory response [35,36]. We therefore
Figure 3. Immunohistochemical examination of MPO expression in mouse retinas following subretinal delivery of compacted DNA
nanoparticles or saline. A. Shown are representative images of immunohistochemical labeling of MPO on retinal sections of eyes injected with
nanoparticles (1.0 and 3.0 mg) or saline at 1, 2, 4 and 7 days PI. No MPO positive labeling was detected in these retinas. B. Shown are representative
images of control assays. MPO immunoreactivity was detected in the Bacillus cereus endophthalmitis eyes (middle panel, B. cereus eye) and in the
mouse inflammatory corneal sections (right panel, Ad37 cornea). OS, outer segment; ONL, outer nuclear layer; INL, inner nuclear layer; GCL, ganglion
cell layer; CE, corneal epithelium; CS, corneal stroma; EN, corneal endothelium. Scale bar, 50 mm.
doi:10.1371/journal.pone.0007410.g003
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had been injected with DNA nanoparticles.
KC is a potent chemo-attractant and neutrophil activator and is
primarily involved in the initiation and amplification of acute
inflammatory reaction processes. It can be produced in response to
inflammatory stimuli by a variety of cells types, including
macrophages, neutrophils, epithelial cells, and endothelial cells. Since
induction of KC in retinas has been observed in response to a variety
oflocal environmentalalterations [34,37], we examined expression of
KC in the retinas of eyes that had been injected. Using ELISA, we
detected no elevation of KC levels in retinas of saline- or
nanoparticle-injected eyes (Figure 5A). As before, the Bacillus cereus
Figure 4. Immunofluorescence examination of F4/80 expression in mouse retinas following subretinal delivery of compacted DNA
nanoparticles or saline. A–B. Shown are representative images of immunofluorescent examination of F4/80 on retinal sections of eyes that were
injected with nanoparticles at (0.3, 1.0 and 3.0 mg) or saline at PI-2 (A); or with 1.0 mg nanoparticle at 1, 2, 4 and 7 days PI (B). No F4/80 positive
labeling was detected in these retinal sections. C. F4/80 immunoreactivity was detected in the Bacillus cereus endophthalmitis eyes (B. cereus retina)
and in the mouse inflammatory corneal sections (Ad-37 cornea). RPE, retinal pigment epithelium; OS, outer segment; ONL, outer nuclear layer; INL,
inner nuclear layer; CE, corneal epithelium; CS, corneal stroma; EN, corneal endothelium. Scale bar, 40 mm.
doi:10.1371/journal.pone.0007410.g004
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included as positive controls. A striking elevation of KC was detected
in these samples (Figure 5A). To confirm our ELISA results, we
examined KC mRNA levels in the injected eyes by quantitative real-
time (qRT)-PCR. We detected a transient elevation of KC mRNA
level in retinas of injected eyes at PI-1. As shown in Figure 5B, KC
mRNA levels were increased 3–4 fold in eyes that had been injected
with either nanoparticles or with saline at PI-1, but returned to
control level at PI-2 (Figure 5B). The concurrent elevation of KC
levels in saline and nanoparticle injected eyes suggests that the
increase was related to the sub-retinal injection procedure and was
not a toxic response to the nanoparticles.
MCP-1 is a member of the small inducible gene family and a
member of the chemokine family. It is produced by a variety of
cells, including monocytes/macrophages, fibroblasts, and epithe-
lial and endothelial cells. It plays a role in the recruitment of
monocytes to sites of injury or infection and is a potent monocyte
agonist [36]. Induction of MCP-1 in retinas has been observed in
animal models of ischemia reperfusion [35] and has been shown to
mediate experimental retinal detachment-induced photoreceptor
apoptosis [38]. We therefore examined expression of MCP-1 in
the injected retinas by using ELISA and qRT-PCR. A transient
increase of MCP-1 protein and mRNA at PI-1 was detected in the
retinas following subretinal injection. As shown in Figure 6, the
Figure 5. Examination of KC expression in mouse retinas following subretinal delivery of compacted DNA nanoparticles or saline.
ELISA (A) and qRT-PCR (B) were performed to determine KC expression in the retinas of eyes that had been subjected to nanoparticles, saline or mock
injection. Assays were performed at 1, 2, 4 and 7 days PI. Ad-37 cornea and Bacillus cereus eye samples were included as positive controls in the ELISA.
No elevation of KC protein was detected in the injected retinas. A significant elevation of KC was detected in the Bacillus cereus endophthalmitis eyes
(B. cereus eye) and in the inflammatory corneal samples (Ad-37 cornea). KC mRNA levels were significantly elevated in both nanoparticle- and saline-
injected retinas at PI-1, compared to the level in the mock injected samples. KC mRNA levels returned to baseline at PI-2. The values shown represent
means6SEM of assays from 3–5 injected mice. * P,0.05, compared to mock injected.
doi:10.1371/journal.pone.0007410.g005
Figure 6. Examination of MCP-1 expression in mouse retinas following subretinal delivery of compacted DNA nanoparticles or
saline. ELISA (A) and qRT-PCR (B) were performed to determine expression of MCP-1 in the retinas of eyes that underwent nanoparticle, saline, or
mock injection. Assays were performed at 1, 2, 4 and 7 days PI. Ad-37 cornea and Bacillus cereus eye samples were included as positive controls in the
ELISA. Levels of MCP-1 protein and mRNA were significantly elevated at PI-1 in both nanoparticle- and saline-injected retinas, compared to the mock
injected samples, but returned to the control value at PI-2. A significant elevation of MCP-1 was detected in the Bacillus cereus endophthalmitis eyes
(B. cereus eye) and in the inflammatory corneal samples (Ad-37 cornea). The values shown represent the means6SEM of assays from 3–5 injected
mice. * P,0.05, compared to mock injected.
doi:10.1371/journal.pone.0007410.g006
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injected eyes were not different from each other but were about 3–
4 fold higher than that in the mock injected eyes. The levels of
MCP-1 protein or mRNA returned to control levels by PI-2
(Figure 6). As shown in Figure 6A, markedly elevated levels of
MCP-1 were detected in the Bacillus cereus endophthalmitis eyes
and in the inflammatory cornea samples.
TNF-a is produced by activated macrophages/monocytes, and
is involved in the acute phase inflammatory reaction. TNF-a is
also involved in other types of pathophysiological activities
including apoptotic cell death, cellular proliferation, differentia-
tion, and tumorogenesis. It has been reported that TNF-a is
expressed and up-regulated in human retinas with proliferative
retinopathy [39,40]. Along with MCP-1, induction of TNF-a has
also been shown to mediate experimental retinal detachment-
induced photoreceptor apoptosis [38]. Hence we examined
expression of TNF-a in retinas of injected eyes. As shown in
Figure 7A, no significant elevation of TNF-a was detected in
retinas following subretinal delivery of nanoparticles. In contrast,
TNF-a level was significantly increased in the experimental Bacillus
cereus endophthalmitis eyes. qRT-PCR analysis showed that no
significant elevation of TNF-a mRNA was detected in the
nanoparticle or saline injected eyes (Figure 7B). Protein and
mRNA levels of all the chemokines tested in the mock injected
eyes were not different from those in the untouched control eyes
(data for uninjected control eyes are not shown).
Discussion
Safety and toxicity testing is a critical component of the
development of clinically viable treatments. In this study we show
that the CK30PEG-compacted DNA nanoparticles containing a
CMV-EGFP expression vector are non-toxic and well-tolerated in
the murine eye after subretinal injection. We report no infiltration
of PMNs, macrophages, or other inflammatory cells after
nanoparticle injection. We also report no nanoparticle-associated
alterations in chemokine expression. Transient, early-onset
elevations in MCP-1 and KC were detected in nanoparticle and
saline injected eyes, and levels of these chemokines quickly
returned to normal. Hence, our data indicate that this transient
upregulation is likely due to the injection procedure and not the
nanoparticle itself.
The eye is an attractive target for gene therapy because of its
accessibility, its immune privilege, and numerous genetic disor-
ders. A number of non-viral methods, including electroporation of
selected genes [41], injection of antisense oligonucleotides [42] and
direct topical delivery (eye drops) using the poly(ethylene oxide)-
poly(propylene oxide)-poly(ethylene oxide) (PEO-PPO-PEO) block
copolymers [43], have been tested for management of a variety of
eye diseases from cornea complications, to diabetic retinopathy
and retinal degenerations [42,44,45]. Previous promising results
have come from delivery of CK30PEG compacted DNA
nanoparticles to the subretinal space [14,21]. We have shown it
to be an effective strategy to rescue retinal disease models and are
economically and practically advantageous. Here we take the next
step and demonstrate that these nanoparticles are also safe and
well-tolerated. We detect no significant local inflammatory
response or toxicity; information essential and required before
any clinic trials can be proposed. This information is doubly
important given recent evidence suggesting that some types of
nanoparticles do cause a cytotoxic response [46,47,48]. Related
work studying the safety of non-viral vector gene delivery suggests
that cytotoxic effects are dependent on the type of vector, the
DNA/vector ratio, and the type of transfected cell [49], suggesting
that each type of particle may need to be tested independently.
This work is the first study to characterize the local toxic and
inflammatory response of retinal tissues to the CK30PEG
compacted DNA nanoparticles.
The CK30PEG compacted DNA nanoparticles have been
shown to be effective in delivering transgenes to multiple tissues of
the lung, brain and eye, and can drive robust expression in both
dividing and post-mitotic cells [14,15,16,17,19,20]. The nanopar-
ticles are stable in saline and serum, and have been shown to enter
cells by a non-traditional mechanism involving specific binding to
cell surface nucleolin followed by direct trafficking to the nucleus
[50]. A phase I/II clinical trial shows that CK30PEG nanopar-
ticles containing a CFTR vector partially correct CFTR function
in CF subjects after intranasal delivery [19]. The safety of airway
delivery of these nanoparticles is well documented both in mouse
models and in this clinical trial [18,19]. Following administration
Figure 7. Examination of TNF-a expression in mouse retinas following subretinal delivery of compacted DNA nanoparticles or
saline. ELISA (A) and qRT-PCR (B) were performed to determine expression of TNF-a in the retinas of injected eyes. Assays were performed at 1, 2, 4
and 7 days PI. No significant elevation of TNF-a protein or mRNA was detected in the injected retinas. A significant elevation of TNF-a detected by
ELISA was shown in the Bacillus cereus endophthalmitis eyes (B. cereus eye). The values shown represent the means6SEM of assays from 3–5 injected
mice.
doi:10.1371/journal.pone.0007410.g007
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alterations in serum chemistry, hematologic parameters, serum
complement levels, IL-6 levels, MIP-2 levels, or in the activity,
growth, and grooming of the mice [18]. Only at very high doses
(100 mg DNA) was there a modest increase in bronchoalveolar
(BAL) neutrophils, a modest increase in BAL IL-6 and KC levels,
and a trace to 1+ infiltrate of mononuclear cells surrounding
pulmonary veins. The double-blind, dose escalation clinical trial
indicated no clinical or laboratory evidence of nanoparticle
toxicity [19]. No elevations of IL-6, IL-8, complement, or C-
reactive protein in serum or in nasal washings were detected in
patients receiving the nanoparticles [19]. These results indicate
that CK30PEG nanoparticles encoding CFTR are a promising
candidate for CF therapy.
Ocular delivery of CK30PEG DNA nanoparticles has been
shown to direct efficient transgene expression in various ocular
tissues depending on the route of injection [14]. However,
measuring the local inflammatory response to such administration
remained a critical step for the further development of these
nanoparticles as an ocular treatment strategy. This work
investigated the toxic and inflammatory response of retinal tissue
to CK30PEG DNA nanoparticles following subretinal delivery.
We did not detect any infiltration of inflammatory cells by
histological examination or by examination of macrophage/
myeloid markers. Up-regulation of the chemokines KC, MCP-1,
and TNF-a in eye tissues has been documented in a variety of
pathological conditions in the eyes. However, when we examined
the protein levels of these inflammatory chemokines we detected
only a transient elevation of MCP-1. Importantly, this elevation
was detected in eyes that had been injected with either
nanoparticles or saline and is thus likely related to the subretinal
injection procedure rather than nanoparticle-associated toxicity.
MCP-1 in the retina may come from RPE cells [51,52] as well as
infiltrated inflammatory cells. As we did not detect clear cell
infiltration, MCP-1 detected in the retina was likely released from
RPE cells. We did observe a transient elevation of KC mRNA but
not protein at PI-1 in both nanoparticle- and saline-injected
retinas. This may reflect a more sensitive detection of mRNA by
qRT-PCR than ELISA for this molecule. We also cannot exclude
the possibility that the protein level was not altered even though
there was an elevation of mRNA. Our current observations on the
lack of overt nanoparticle-associated toxicity are in keeping with
our previous work which demonstrated that saline and nanopar-
ticle injected eyes had no differences in maximum ERG amplitude
(scotopic or photopic) and that after recovery from the subretinal
injection procedure the ERG recordings were not different from
uninjected control eyes [14].
In summary, this work evaluated the local inflammatory and
cellular toxic response to subretinal delivery of compacted DNA
nanoparticles. We found no infiltration of inflammatory cells and
only a mild and transitory increase in MCP-1 protein that was due
to the subretinal injection procedure. Combined with our previous
findings, results of this study indicate that subretinal delivery of
DNA nanoparticles is a safe and non-toxic approach for ocular
gene therapy. This favorable safety profile confirms that
compacted DNA nanoparticles can be developed as a clinically
relevant therapeutic strategy for the treatment of inherited retinal
diseases.
Materials and Methods
Plasmid and Nanoparticle Formulation
pZEOGFP5.1 plasmid encoding the EGFP cDNA transcrip-
tionally-controlled by the CMV immediate-early promoter and
enhancer [16] was used for the nanoparticle formulation. The
nanoparticles were formulated by mixing plasmid DNA with
CK30PEG10K, a 30-mer lysine peptide with an N-terminal
cysteine that is conjugated via a maleimide linkage to 10 kDa
polyethylene glycol, as previously described [15]. These nanopar-
ticles consist of a single molecule of DNA per complex [16], have a
rod-like morphology with a diameter of 8–11 nm and a length of
150–200 nm [17], are stable in saline for years at 4uC [53], and
have a zeta potential of zero [16]. The nanoparticles used in this
study were identical in formulation to those previously shown to be
capable of driving high levels of gene expression after ocular
delivery [14,21].
Animals
One-month old C57BL/6 mice (25–30 g) (Charles River
Laboratories, Wilmington, MA) were used in this study. All mice
studied were maintained in a breeding colony under cyclic light
(12-hour light-dark) conditions; cage illumination was approxi-
mately 7 foot-candles during the light cycle. All experiments were
approved by the local Institutional Animal Care and Use
Committees (Oklahoma City, OK, U.S.A.) and conformed to
the guidelines on the care and use of animals adopted by the
Society for Neuroscience and the Association for Research in
Vision and Ophthalmology (Rockville, MD, U.S.A.).
Subretinal Injection
Transvitreal subretinal injections were performed as described
by Nour et al. [54]. The operations were performed under a Carl
Zeiss OPMI VISU 140 surgical operating microscope (Thorn-
wood, NY). After anesthesia and complete dilation was achieved, a
drop of 2.5% methylcellulose was added to the corneal surface to
visualize the fundus. A 28-gauge beveled hypodermic needle (BD
Biosciences, Franklin Lakes, NJ) was used to puncture the cornea
carefully, avoiding any contact with the lens. The transvitreal
subretinal injections were performed with a 33-gauge blunt needle
(Hamilton Co., Reno, NV) using a NanoFil microsyringe injector
system (World Precision Instruments, Sarasota, FL). 1.0 mLo f
saline or saline containing DNA nanoparticles at 0.3, 1.0 and
3.0 mg/mL was injected into the subretinal space. These doses have
been shown to induce expression of transgenes in ocular tissues
[14]. Three to five animals were included in each injection group.
A group of animals were anesthetized and underwent corneal
puncture without subretinal injection (mock injection control).
Retinas or eyes were collected at 1, 2, 4 and 7 days post-injection
(PI).
Histopathology, Immunohistochemistry and
Immunofluorescence
Mouse eyes were enucleated and fixed with 4% formaldehyde
(Polysciences, Inc., Warrington, PA) in 0.1 M sodium phosphate
buffer, pH 7.4 for 16 h at 4uC. After 30 minutes of initial fixation,
a small incision was made on the cornea for better fixative
penetration. The tissues were then dehydrated through a graded
ethanol series and embedded in paraffin. Sections (5 mm thick)
were cut along the horizontal meridian throughout the eye, passed
through the optic nerve, and were mounted on positively charged
slides before being air dried overnight. H&E staining was
performed.
Immunohistochemistry was performed as described by Chinta-
kuntlawar et al. [26]. Briefly, retinal sections were treated with
0.01 M citrate buffer (Biopath, Oklahoma City, OK) for epitope
retrieval to facilitate antibody recognition. Nonspecific binding
was blocked using protein block (Dako, Carpinteria, CA)
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Diego, CA) and 5% rat serum (Jackson ImmunoResearch
Laboratories, West Grove, PA). Slides were then incubated with
a rabbit polyclonal antibody against myeloperoxidase (MPO)
(1:200) (Neomarkers, Fremont, CA) followed by incubation with
biotinylated-polyclonal goat anti-rabbit IgG (1:500) (Dako, Inc.,
Carpenteria, CA). Immunodetection was performed with biotin-
streptavidin and alkaline phosphatase according to the manufac-
turer’s instructions (Dako, Inc., Carpenteria, CA). The Dako
cytomation Liquid Permanent Red (LPR) substrate-chromogen
system (Dako, Inc.) was used to develop the APase reaction
product. Slides were counterstained with hematoxylin, cover-
slipped using a synthetic resin, and photographed (Axiovert 135;
Carl Zeiss Meditec, Inc.).
Immunofluorescence labeling was performed as described
previously [14]. Briefly, after deparaffinization, sections were
blocked with PBS containing 5% BSA and 0.5% Triton-X 100 for
1 h at room temperature. Primary antibody incubation with rabbit
polyclonal anti-GFP (Molecular Probes Inc. Carlsbad, CA; 1:250)
or with rat monoclonal anti-F4/80 (Serotec, Oxford, UK; 1:500)
was performed at room temperature for 2 h or overnight at 4uC.
Following incubation with fluorescence-conjugated secondary
antibody (at room temperature for 60 min) and rinses, slides were
incubated with DAPI (1:10,000, Sigma, St. Louis, MO) for 15
minutes to counterstain nuclei, mounted, and cover-slipped.
Fluorescent signals were visualized and images were captured
using an Olympus AX70 fluorescence microscope (Olympus
Corp., Center Valley, PA) with the QCapture imaging software
(QImaging Corp., Surrey, BC, Canada).
ELISA
Sandwich ELISA kits which test for the chemokine MCP-1,
mouse KC, and mouse TNF-a were obtained from R&D Systems
Inc. (Minneapolis, MN). Assays were performed as recommended
by the manufacturer, read using a microplate reader (Molecular
Devices, Sunnyvale, CA), and analyzed using SOFTmax software
(Molecular Devices, Sunnyvale, CA). Briefly, retinas were
homogenized on ice in PBS containing 10 ug/mL leupeptin,
1 mM phenylmethylsulfonyl (PMSF) and 1 ug/mL aprotinin
(Sigma-Aldrich, St. Louis, MO). Lysates were centrifuged at
10,000 g for 10 minutes. Supernatants were used undiluted for
ELISA experiments. Each sample and the standards provided
were analyzed in duplicate, and each time point/treatment was
repeated in three to five independent experiments.
RNA Isolation and Reverse Transcription
Total RNA was isolated from mouse retinas, three to four
individual retinas per condition, using Trizol reagent as per the
manufacturer’s instructions (Invitrogen, Carlsbad, CA). DNAse
treatment (Invitrogen) was performed to prevent genomic/
nanoparticle DNA contamination and the concentration of RNA
was determined using spectrophotometry. Two micrograms of
total RNA was reverse transcribed using an oligo-dT primer and
SuperScript III reverse transcriptase (Invitrogen) according to
instructions provided by the manufacturer.
Quantitative Real -Time PCR
PCR Universal Master Mix and primer mixes containing the
primers and probes for mouse chemokines MCP-1, KC, TNF-a
and the internal control gene hypoxanthine guanine phosphor-
ibosyl transferase 1 (HPRT-1) were obtained from Applied
Biosystems Inc. (Foster City, CA) and used according to the
manufacturer’s recommendation. qRT-PCR amplification was
performed using a Bio-Rad i-cycler real-time PCR machine (Bio-
Rad, Hercules, CA). Each set of primers bridged exons to ensure
amplification of cDNA only. Chemokines were tested and
normalized against HPRT-1. Normalization was done using the
formula 10/2
DcT where DcT = cT (gene of interest) – cT (HPRT-
1) as described previously [55].
Inflammatory Eye Samples Used As Positive Controls in
This Study
Two types of inflammatory eye samples were used in this study
as positive controls. The first type was eyes with experimental
Bacillus cereus endophthalmitis. The endophthalmitis was induced
in C57 BL/6 mice by intravitreal injection of 100 colony-forming
units (CFUs) of Bacillus cereus and eyes were collected 8 h PI. This is
a well established experimental endophthalmitis model and
elevation of the inflammatory chemokines has been characterized
in the various ocular tissues including the retina [22,24,25]. These
samples were kindly provided by Dr. Michelle Callegan at the
Dean A. McGee Eye Institute (Oklahoma City, OK). The second
type of positive control was cornea tissue with experimental
inflammation induced by injection of adenovirus type 37 (Ad-37).
This model of corneal keratitis is also known to be associated with
up-regulation of inflammatory chemokines and infiltration of
PMNs [26]. The cornea samples were kindly provided by Dr.
James Chodosh at the Dean A. McGee Eye Institute (Oklahoma
City, OK). These inflammatory eye samples were used in
immunohistochemistry, immunofluorescence labeling, and
ELISA.
Statistical Analysis
ELISA and qRT-PCR for chemokine expression were each
performed using retinas from 3–5 injected mice. Mean values were
compared by one-way analysis of variance (ANOVA) with
Bonferroni’s post-hoc pair-wise comparisons (GraphPad Prism
4.0; GraphPad, San Diego, CA).
Supporting Information
Figure S1 Histological examination of inflammatory cell
infiltration in mouse retinas following subretinal delivery of
compacted DNA nanoparticles or saline. A. Shown are represen-
tative images of H&E stained retinal sections of eyes injected with
nanoparticles (1.0 and 3.0 mg) or saline at 1, 2, 4 and 7 days PI. No
infiltration of inflammatory cells was detected in the injected
retinas. B. Shown are representative images of control assays.
Infiltrating cells were detected in retinal sections of Bacillus cereus
endophthalmitis eyes (middle panel, shown by arrows) and in
corneal sections of Ad37-infected eyes (right panel, shown by
arrows). No infiltration was detected on retinal section of untreated
eyes (left panel). OS, outer segment; ONL, outer nuclear layer;
INL, inner nuclear layer; IPL, inner plexiform layer; GCL,
ganglion cell layer; CE, corneal epithelium; CS, corneal stroma;
EN, corneal endothelium. Scale bar, 100 mm.
Found at: doi:10.1371/journal.pone.0007410.s001 (8.19 MB TIF)
Figure S2 Immunohistochemical examination of MPO expres-
sion in mouse retinas following subretinal delivery of compacted
DNA nanoparticles or saline. A. Shown are representative images
of immunohistochemical labeling of MPO on retinal sections of
eyes injected with nanoparticles (1.0 and 3.0 mg) or saline at 1, 2, 4
and 7 days PI. No MPO positive labeling was detected in these
retinas. B. Shown are representative images of control assays.
MPO immunoreactivity was detected in the Bacillus cereus
endophthalmitis eyes (B. cereus eye) (middle panel) and in the
mouse inflammatory corneal sections (Ad37-cornea) (right panel).
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layer; GCL, ganglion cell layer; CE, corneal epithelium; CS,
corneal stroma; EN, corneal endothelium. Scale bar, 100 mm.
Found at: doi:10.1371/journal.pone.0007410.s002 (2.26 MB TIF)
Figure S3 Immunofluorescence examination of F4/80 expres-
sion in mouse retinas following subretinal delivery of compacted
DNA nanoparticles or saline. Shown are representative images of
immunofluorescent examination of F4/80 on retinal sections of
eyes that were injected with nanoparticles at (0.3, 1.0 and 3.0 mg)
or saline at PI-2 (A); or with 1.0 mg nanoparticle at 1, 2, 4 and 7
days PI (B). No F4/80 positive labeling was detected in these
retinal sections. F4/80 immunoreactivity was detected in the
Bacillus cereus endophthalmitis eyes (B. cereus retina) and in the
mouse inflammatory corneal sections (Ad-37 cornea) (C). RPE,
retinal pigment epithelium; OS, outer segment; ONL, outer
nuclear layer; INL, inner nuclear layer; CE, corneal epithelium;
CS, corneal stroma; EN, corneal endothelium. Scale bar, 100 mm.
Found at: doi:10.1371/journal.pone.0007410.s003 (5.41 MB TIF)
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